Table 2.
Plasma/serum/tissue concentrations of amantadine in animals
| Species | Dose (mg/kg), route | Use | Body fluids, µM | Brain—CSF/ECF, µM | Brain homog, µM | References |
|---|---|---|---|---|---|---|
| Rat |
25, p.o. 50, p.o. 100, p.o. |
Antiparkinsonian-like activity |
4.5 (s) 10.5 (s) 21.0 (s) |
– 90.0 – |
Danysz et al. (1994b) | |
|
15, i.p. 45, i.p. 90, i.p. |
Pharmacokinetics in relation to antidyskinetic effects |
14.8 (p) 37.2 (p) 132.6 (p) |
Brigham et al. (2018) | |||
| 100 (s.c.) | PK study, infusion, dose per day | ca. 8 (s) | ca. 4.6/4.0 | ca. 70 | Hesselink et al. (1999) | |
|
23, i.p. 46, i.p. 92, i.p. |
Antiparkinsonian-like activity, pharmacokinetics, microdialysis |
7.7 11.9 23.1 |
Kornhuber et al. (1995) and Quack et al. (1995) | |||
|
5, i.p. 15, i.p. 45, i.p. |
TBI, repetitive treatment 3 × per day for 16 days after TBI |
5.3 (s) 21.3 (s) 63.9 (s) |
Wang et al. (2014) | |||
| 100, s.c. | Neuroprotection study, dose per day—infusion for 14 days | 8.77 (s) | 107.5 | Wenk et al. (1996) | ||
| Mouse | 25, p.o. | Pharmacokinetics | 42.7 (b) | Bleidner et al. (1965) | ||
|
10, i.p. 30, i.p. 60, i.p. |
Pharmacokinetics in relation to antidyskinetic effects |
6.8 (p) 19.9 (p) 47 (p) |
Brigham et al. (2018) | |||
| Macaques |
1, i.p. 3, i.p. 10, i.p 30, i.p. |
Pharmacokinetics in relation to antidyskinetic effects |
0.86 p) 2.9 (p) 8.5 (p) 24.7 (p) |
Brigham et al. (2018) |
s serum, p plasma, b blood, CSF cerebrospinal fluid, ECF extracellular fluid, homog. homogenates